Bilaketaren emaitzak - Shih‐Feng Cho

  • Erakusten 1 - 14 emaitzak -- 14
Findu emaitzak
  1. 1
    Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

    Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1 nork Yu‐Tzu Tai, Shih‐Feng Cho, Kenneth C. Anderson

    Argitaratua 2018
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

    Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy nork Shih‐Feng Cho, Kenneth C. Anderson, Yu‐Tzu Tai

    Argitaratua 2018
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma

    Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma nork Hui‐Ching Wang, Leong‐Perng Chan, Shih‐Feng Cho

    Argitaratua 2019
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma

    Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma nork Shih‐Feng Cho, Lijie Xing, Kenneth C. Anderson, Yu‐Tzu Tai

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Bispecific antibodies in multiple myeloma treatment: A journey in progress

    Bispecific antibodies in multiple myeloma treatment: A journey in progress nork Shih‐Feng Cho, Tsung‐Jang Yeh, Kenneth C. Anderson, Yu-Tzu Tai

    Argitaratua 2022
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  6. 6
    BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

    BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma nork Shih‐Feng Cho, Liang Lin, Lijie Xing, Yuyin Li, Tengteng Yu, Kenneth C. Anderson, Yu‐Tzu Tai

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy

    Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with diffuse large B-cell lymphoma r... nork Chin-Chuan Chang, Shih‐Feng Cho, Ya‐Wen Chuang, Chia-Yang Lin, Shu-Min Chang, Wen-Ling Hsu, Ying‐Fong Huang

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression

    MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression nork Shih‐Feng Cho, Yu-Li Chang, Chao‐Sung Chang, Sheng-Fung Lin, Yi‐Chang Liu, Hui‐Hua Hsiao, Jan‐Gowth Chang, Ta‐Chih Liu

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

    A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma nork Lijie Xing, Liang Lin, Tengteng Yu, Yuyin Li, Shih‐Feng Cho, Jiye Liu, Kenneth Wen, Phillip A. Hsieh, Krista Kinneer, Nikhil C. Munshi, Kenneth C. Anderson, Yu‐Tzu Tai

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

    γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation nork Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih‐Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil C. Munshi, Kenneth C. Anderson, Yu‐Tzu Tai

    Argitaratua 2022
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications

    APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications nork Yu‐Tzu Tai, Liang Lin, Lijie Xing, Shih‐Feng Cho, Tengteng Yu, Chirag Acharya, Kenneth Wen, Phillip A. Hsieh, John Dulos, Andrea van Elsas, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models

    The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models nork Shih‐Feng Cho, Liang Lin, Lijie Xing, Yuyin Li, Kenneth Wen, Tengteng Yu, Phillip A. Hsieh, Nikhil C. Munshi, Joachim Wahl, Katja Matthes, Matthias Friedrich, Tara Arvedson, Kenneth C. Anderson, Yu‐Tzu Tai

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma

    Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma nork Liang Lin, Shih‐Feng Cho, Lijie Xing, Kenneth Wen, Yuyin Li, Tengteng Yu, Phillip A. Hsieh, Hailin Chen, Metin Kurtoğlu, Yi Zhang, Charles A. Stewart, Nikhil C. Munshi, Kenneth C. Anderson, Yu‐Tzu Tai

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

    VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo nork Tengteng Yu, Bharat K. R. Chaganty, Liang Lin, Lijie Xing, Boopathy Ramakrishnan, Kenneth Wen, Phillip A. Hsieh, Andrew M. Wollacott, Karthik Viswanathan, Hedy Adari, Shih‐Feng Cho, Yuyin Li, Hailin Chen, Wenjuan Yang, Yan Xu, Gang An, Lugui Qiu, Nikhil C. Munshi, Gregory J. Babcock, Zachary Shriver, James R. Myette, Kenneth C. Anderson, Yu‐Tzu Tai

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: